551 related articles for article (PubMed ID: 12761329)
1. Cyclic nucleotide phosphodiesterase 5 and sildenafil: promises realized.
Manganiello V
Mol Pharmacol; 2003 Jun; 63(6):1209-11. PubMed ID: 12761329
[No Abstract] [Full Text] [Related]
2. Sildenafil inhibits phosphodiesterase type 5 in human clitoral corpus cavernosum smooth muscle.
Park K; Moreland RB; Goldstein I; Atala A; Traish A
Biochem Biophys Res Commun; 1998 Aug; 249(3):612-7. PubMed ID: 9731184
[TBL] [Abstract][Full Text] [Related]
3. Type 5 phosphodiesterase inhibition: the focus shifts to the heart.
Semigran MJ
Circulation; 2005 Oct; 112(17):2589-91. PubMed ID: 16246958
[No Abstract] [Full Text] [Related]
4. [Phosphodiesterase 5--the enzyme inhibited by sildenafil (Viagra)].
Sandberg M; Natarajan V
Tidsskr Nor Laegeforen; 1999 Mar; 119(7):945-9. PubMed ID: 10210955
[TBL] [Abstract][Full Text] [Related]
5. The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5.
Dunkern TR; Hatzelmann A
Cell Signal; 2005 Mar; 17(3):331-9. PubMed ID: 15567064
[TBL] [Abstract][Full Text] [Related]
6. High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients.
Weeks JL; Zoraghi R; Beasley A; Sekhar KR; Francis SH; Corbin JD
Int J Impot Res; 2005; 17(1):5-9. PubMed ID: 15538396
[TBL] [Abstract][Full Text] [Related]
7. Sildenafil increases cerebrovascular reactivity: a transcranial Doppler study.
Brenner S
Neurology; 2006 May; 66(9):1455-6; author reply 1455-6. PubMed ID: 16682690
[No Abstract] [Full Text] [Related]
8. Inhibition of type-5 phosphodiesterase: promising therapy for pulmonary hypertension.
Watanabe H
Intern Med; 2004 Oct; 43(10):891-3. PubMed ID: 15575233
[No Abstract] [Full Text] [Related]
9. [3H]sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP.
Corbin JD; Blount MA; Weeks JL; Beasley A; Kuhn KP; Ho YS; Saidi LF; Hurley JH; Kotera J; Francis SH
Mol Pharmacol; 2003 Jun; 63(6):1364-72. PubMed ID: 12761347
[TBL] [Abstract][Full Text] [Related]
10. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation.
Blount MA; Beasley A; Zoraghi R; Sekhar KR; Bessay EP; Francis SH; Corbin JD
Mol Pharmacol; 2004 Jul; 66(1):144-52. PubMed ID: 15213306
[TBL] [Abstract][Full Text] [Related]
11. Sildenafil reverses O2 constriction of the rabbit ductus arteriosus by inhibiting type 5 phosphodiesterase and activating BK(Ca) channels.
Thébaud B; Michelakis E; Wu XC; Harry G; Hashimoto K; Archer SL
Pediatr Res; 2002 Jul; 52(1):19-24. PubMed ID: 12084842
[TBL] [Abstract][Full Text] [Related]
12. KF31327, a new potent and selective inhibitor of cyclic nucleotide phosphodiesterase 5.
Hirose R; Okumura H; Yoshimatsu A; Irie J; Onoda Y; Nomoto Y; Takai H; Ohno T; Ichimura M
Eur J Pharmacol; 2001 Nov; 431(1):17-24. PubMed ID: 11716838
[TBL] [Abstract][Full Text] [Related]
13. A novel compound JPM8: in vivo penile activity promotion in rats, effect on the relaxation and cGMP/cAMP accumulation in isolated rabbit corpora cavernosa.
El-Thaher TS; Khatib S; Saleem M; Shnoudeh A; Badwan AA
Int J Impot Res; 2002 Dec; 14(6):453-61. PubMed ID: 12494277
[TBL] [Abstract][Full Text] [Related]
14. Tadalafil and vardenafil.
Neumeyer K; Kirkpatrick P
Nat Rev Drug Discov; 2004 Apr; 3(4):295-6. PubMed ID: 15124623
[No Abstract] [Full Text] [Related]
15. Effects of phosphodiesterase 5 inhibitor on pulmonary vascular reactivity in the fetal lamb.
Jaillard S; Larrue B; Deruelle P; Delelis A; Rakza T; Butrous G; Storme L
Ann Thorac Surg; 2006 Mar; 81(3):935-42. PubMed ID: 16488698
[TBL] [Abstract][Full Text] [Related]
16. The CYP2C9 genotype does not influence sildenafil pharmacokinetics in healthy volunteers.
Jetter A; Lazar A; Schömig E; Fuhr U; Kinzig-Schippers M; Sörgel F
Clin Pharmacol Ther; 2005 Oct; 78(4):441-3. PubMed ID: 16198665
[No Abstract] [Full Text] [Related]
17. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells.
Wharton J; Strange JW; Møller GM; Growcott EJ; Ren X; Franklyn AP; Phillips SC; Wilkins MR
Am J Respir Crit Care Med; 2005 Jul; 172(1):105-13. PubMed ID: 15817798
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and phosphodiesterase 5 inhibitory activity of new sildenafil analogues containing a phosphonate group in the 5(')-sulfonamide moiety of phenyl ring.
Kim DK; Young Lee J; Park HJ; Minh Thai K
Bioorg Med Chem Lett; 2004 May; 14(9):2099-103. PubMed ID: 15080987
[TBL] [Abstract][Full Text] [Related]
19. [7 years PDE-5 inhibitor for therapy of erection disorders].
Krankenpfl J; 2005; 43(7-10):267. PubMed ID: 16518894
[No Abstract] [Full Text] [Related]
20. In vivo dilation of fetal and neonatal ductus arteriosus by inhibition of phosphodiesterase-5 in rats.
Momma K; Toyoshima K; Imamura S; Nakanishi T
Pediatr Res; 2005 Jul; 58(1):42-5. PubMed ID: 15774847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
